ReviewCancers2021
Surgical Treatment of Pancreatic Ductal Adenocarcinoma.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Discovery of a Secretory Granule Lumen-Enriched Serum Protein Signature in Resectable Pancreatic Ductal Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Extraordinary enlargement of the main pancreatic duct dilatation in pancreatic ductal adenocarcinoma - a case report.International journal of surgery case reports · 2026Article
- Afferent loop syndrome secondary to recurrent pancreatic adenocarcinoma post-Whipple procedure: case report.Frontiers in oncology · 2026Article
- Integrated transcriptomic and functional characterization of Claudin-1 reveals its oncogenic and immunomodulatory roles in pancreatic ductal adenocarcinoma.Tissue barriers · 2026Article
- Differentiating cytology of pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors by EUS-FNA through hyperspectral imaging technology combined with artificial intelligence.Therapeutic advances in gastroenterology · 2026Article
- Vascular Resections with PancreaticoduoDenectomy for Pancreatic and Non-pancreatic Periampullary Cancers.Indian journal of surgical oncology · 2025Article
- Synergizing photodynamic therapy and ethanol ablation: Light-activatable sustained-exposure ethanol injection technology for enhanced tumor ablation.Bioengineering & translational medicine · 2025Article
- Role of Neoadjuvant Therapy in Remodeling Surgical Approaches for Gastrointestinal Malignancies.Current gastroenterology reports · 2025Review
- Can AI Be Useful in the Early Detection of Pancreatic Cancer in Patients with New-Onset Diabetes?Biomedicines · 2025Review
- MRI findings of pancreatic intraductal oncocytic papillary neoplasm: three case reports and review of literature.Frontiers in medicine · 2025Article
- Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma.Frontiers in immunology · 2025Review
- Thermosensitive Liposomes for Gemcitabine Delivery to Pancreatic Ductal Adenocarcinoma.Cancers · 2024Article
- Reduction of Postoperative Complications in Pancreatic Surgery by Standardizing Perioperative Management: An Observational Cohort Study.Visceral medicine · 2024Article
- Comparative immune profiling of pancreatic ductal adenocarcinoma progression among South African patients.BMC cancer · 2024Article
- Role of Endoscopic Ultrasound in Pancreatic Cancer Diagnosis and Management.Diagnostics (Basel, Switzerland) · 2024Review
- Endoscopic Ultrasound-Guided Ablation of Premalignant Pancreatic Cysts and Pancreatic Cancer.Diagnostics (Basel, Switzerland) · 2024Review
- Loss ofFrontiers in immunology · 2024Article
- A more radical perspective on surgical approach and outcomes in pancreatic cancer-a narrative review.Journal of gastrointestinal oncology · 2023Review
- Role of microbiota and microbiota-derived short-chain fatty acids in PDAC.Cancer medicine · 2023Review
- Perioperative Drug Treatment in Pancreatic Surgery-A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) represents an aggressive tumor of the digestive system with still low five-year survival of less than 10%. Although there are improvements for multimodal therapy of PDAC, surgery still remains the effective way to treat the disease. Combined with adjuvant and/or neoadjuvant treatment, pancreatic surgery is able to enhance the five-year survival up to around 20%. However, pancreatic resection is always associated with a high risk of complications and regarded as one of the most complex fields in abdominal surgery. This review gives a summary on the surgical treatment for PDAC based on the current literature with a special focus on resection techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.